XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Convertible Preferred Stock - Additional Information (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 6 Months Ended
Oct. 31, 2021
shares
Mar. 31, 2021
USD ($)
$ / shares
shares
Jun. 30, 2021
USD ($)
Mar. 05, 2021
$ / shares
Temporary Equity [Line Items]        
Issuance costs     $ 729  
Net proceeds from issuance of convertible preferred stock     $ 151,581  
Securities Purchase Agreement | Series B Convertible Preferred Stock        
Temporary Equity [Line Items]        
Share sale price per share | $ / shares   $ 1.6458   $ 1.6458
Shares issued | shares   92,356,299    
Gross cash proceeds from issuance of convertible preferred stock   $ 152,000    
Issuance costs   400    
Net proceeds from issuance of convertible preferred stock   $ 151,600    
Reverse stock split description 1-for-6.359 reverse stock split      
Reverse stock split, conversion ratio 0.15725743      
Securities Purchase Agreement | Series B Convertible Preferred Stock | Common Stock        
Temporary Equity [Line Items]        
Convertible preferred stock shares issued upon conversion | shares 16,482,486      
Securities Purchase Agreement | Series B Convertible Preferred Stock | Initial Public Offering        
Temporary Equity [Line Items]        
Number of preferred shares conversion | shares 104,812,248      
Agreements with Pfizer, Inc. and LegoChem Biosciences Inc. | Series B Convertible Preferred Stock        
Temporary Equity [Line Items]        
Shares issued | shares   12,455,949    
Net proceeds from issuance of convertible preferred stock   $ 20,500